anti-CLL-1 CAR T cell therapy (Vor BioPharma)

N/A

Report date: 2025/06/11 10:26:17

Base Information

Drug Nameanti-CLL-1 CAR T cell therapy (Vor BioPharma)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsT lymphocytes stimulantsImmunostimulants

TargetsC-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVor Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesVor Biopharma Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A